Market Intelligence, Clinical Progress, and High-Purity Reagents for Urolithiasis and Metabolic Disease Drug Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for SLC26A1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SLC26A1 Extracellular Loop Recombinant Protein High purity (>95%), Endotoxin controlled. Sequence Verified. HEK293 expressed. |
View SLC26A1 Products |
| Gene Delivery | SLC26A1 Lentivirus Premade Particles Full-length ORF for stable cell line construction and functional transport assays. |
View SLC26A1 Products |
| Benchmark Ab | Anti-SLC26A1 Recombinant Antibody Recombinant positive control for flow cytometry and surface expression validation. |
View SLC26A1 Products |
| Validator | SLC26A1 siRNA Set For target knockdown and functional validation in renal cell models. |
View SLC26A1 Products |
| Related Target A | SLC26A6 Critical homolog for selectivity screening to prevent off-target renal oxalate transport disruption. |
View SLC26A6 Products |
| Related Target B | SLC26A2 Sulfate transporter subfamily member; essential for counter-screening to avoid chondrodysplasia-related toxicity. |
View SLC26A2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Multipass (12-TM) Membrane Conformation | High-titer Lentiviral particles optimized for stable overexpression in HEK293/CHO, preserving native folding. |
| Subfamily Off-target Screening | Homolog panel (SLC26A6, SLC26A2) available as sequence-verified open reading frames (ORFs). |
| Lack of Controls | Sequence-defined recombinant antibodies serving as reliable assay benchmarks. |
| False Positives | Validated siRNA pools included for target-specific knockdown control. |
Live SLC26A1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of SLC26A1 (sat-1) is emerging as a novel approach in managing urolithiasis (kidney stones) and related metabolic disorders. As a major sulfate-oxalate exchanger primarily expressed in the proximal tubule of the kidney and the basolateral membrane of hepatocytes, SLC26A1 modulation holds promise for regulating systemic oxalate homeostasis. The race for SLC26A1 therapeutics is intensifying, with major players shifting focus from traditional systemic inhibitors to gut-restricted or tissue-selective small molecules. As first-generation therapies reach the clinic, the next wave of R&D is targeting precise allosteric modulation to avoid systemic sulfate depletion.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic Consortia, Biotech Startups | Hyperoxaluria, Calcium Oxalate Urolithiasis | Functional Transport Assay (Need Lentivirus for Stable Cell Lines) |
| Monoclonal Antibodies | Biopharma Innovators | Metabolic Disorders, Sulfate Regulation | Epitope Mapping (Need Recombinant Extracellular Loops) |
| Gene Therapy / RNAi | Rare Disease Specialists | SLC26A1 Deficiency, Chondrodysplasia models | Expression Rescue Verification (Need Validated siRNA & Lentivirus) |